Enquirer Consulting Group

Reachable Buyer Map

Prepared for Rosalina Lim · Dexa Medica · August 2026
From the outside, the domestic channel reads as the settled part of this market, so this map leaves it alone. What it covers is the layer outside Indonesia: the companies that buy manufacturing capacity, licenses and finished product from a manufacturer in Southeast Asia, which seat inside each one signs, and roughly how many there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
Pharmaceutical companies across ASEAN
The nearest market and the one where a shared dossier format removes most of the friction. The buyers here fall into two groups that look identical from outside: companies with their own plants that lack a specific capability, and license holders with no manufacturing at all. They ask completely different opening questions.
Who signs: head of external manufacturing, business development director, supply chain director, regulatory affairs lead.
900 to 1,200
licensed pharmaceutical manufacturers and marketing authorization holders across the ASEAN member states; national registers publish the two categories inconsistently
Importers and license holders across Africa and the Middle East
Large, real, and the hardest layer on this page to see from a distance. Each country licenses its own importers and publishes that list in its own format and language, which means the segment cannot be bought and has to be assembled. That difficulty is precisely why it stays open.
Who signs: managing director or country head, head of registration, in-licensing or portfolio manager.
No single register
assembled country by country from national regulator and importer listings, one market at a time
Consumer health and supplement brand owners
A shorter decision than pharma and a much larger count, because a brand owner who outsources production has no plant of their own to defend. Volume commitments are smaller at the start and they scale quickly when a product moves, which makes this the segment most likely to open a first conversation.
Who signs: VP of operations, head of supply, head of quality, and the founder at emerging brands.
2,000 to 3,000
US and European companies registered in vitamin, supplement and consumer health production or wholesale carrying 20 or more people
Mid-size pharma seeking a second manufacturing source
The segment created by the last five years rather than by demand: single-source supply became a board-level risk, and a qualified plant on another continent is now an answer to that. The subset actively searching is invisible in any register, but the population it comes from is countable.
Who signs: VP of external manufacturing, head of CMC, drug product procurement lead, head of quality.
1,200 to 1,600
US and European pharmaceutical manufacturers at 50 or more people; the subset currently searching is a fraction of that and is not separately listed
Institutional and donor procurement
Ministries, multilateral agencies, global funds and foundations buying essential medicines and nutrition products at scale. Slow to open, unusually durable once open, and the only segment here where the requirement is published in advance and in public.
Who signs: procurement officer, supply chain lead, technical program manager, and the prequalification team behind them.
A small named group
they publish tenders and prequalification lists rather than appearing in any buyer register; reached by watching those publications rather than by list building
Natural product and botanical buyers
The buyers for clinically evidenced plant-derived medicine sit across three different registers at once: pharma, supplements and food. No code separates them, so the segment is identified company by company. Small today, and the one on this page with the least competition inside it.
Who signs: head of research and development, category buyer, regulatory affairs lead, head of innovation.
Not enumerated
spread across pharmaceutical, supplement and food registers with no code that isolates them; identified rather than filtered

Where the openings are

1
Two purchases, two seats, one company. Taking a license to a finished product and buying manufacturing capacity are decided by different people who often sit two floors apart: business development on one side, external manufacturing and supply on the other. A single message addressed to the company reaches one of them at best, and usually the wrong one.
2
The buying moment is an event, not a season. A partner exits a market, a plant loses a certification, a dossier reaches renewal, a tender is published. Every one of those is visible from outside, and every one of them opens a window that closes again in weeks. Watching a few thousand companies for those events is mechanical work that no relationship channel can do.
3
Partner selection happens at dossier stage. In most of these markets the manufacturing and licensing decision is settled while the registration file is being built, long before commercial terms are discussed. Arriving after a registration has started means arriving after the decision, which is why timing beats persistence in this segment.
4
The layers that cannot be bought are the ones still open. Importers, institutional buyers and botanical buyers are all reachable and none of them can be pulled off a list. That is a distribution problem rather than a credibility one, and it is the part we build: several thousand named companies, the right seat inside each, worked on a schedule and handed over when it runs.
Built from public market data, counts banded deliberately. Manufacturer and license holder counts come from national regulator listings and published sector statistics rather than one central source, so they indicate the size of each layer rather than an exact extract. Brand owner counts describe registered companies above the micro threshold. Importer, institutional and botanical buying are not recorded as categories in any public register and are described rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com